6	Customer 28. 28880		Confirmation No. 9394
MAR	0 3 2005 O	U.S. Pat	PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 ent and Trademark Office; U.S. DEPARTMENT OF COMMERCE tion of information unless it displays a valid OMB control number.
SATERT	TRADE TAL	Application Number	10/602,447
•	TRANSMITTAL	Filing Date	June 24, 2003
	FORM	First Named Inventor	Erik Ho Fong Wong
}	(to be used for all correspondence after initial filing)	Art Unit	
		Examiner Name	
ţ	Total Number of Pages in This Submission	Attorney Docket Number	00054.US1 (PC24974A)

	ENCLOSURES (Check all that apply)						
	Fee Transmittal Form	Drawing(s)	After Allowance Communication to a Technology Center (TC)				
	Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks AUTHORIZATION TO CHARGE THE F NECESSARY OR CREDIT ANY OVERI 23-0455 IS HEREBY GIVEN.					
	SIGNA	TURE OF APPLICANT, ATTORNEY, O	OR AGENT				
Firm or Indivi	David R. Kurlandsky						
Signa Date	Signature Date						
		ERTIFICATE OF TRANSMISSION/MA	ILING				
Lhorch		assimile transmitted to the LISPTO or deposited with the					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: CommIssioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

first class mail in an envelope addressed to:Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450 on this dat

Linda A. Zerby

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Typed or printed

Signature



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: Erik Ho Fang Wong, et al.

EXAMINER: Unknown

SERIAL NO. : 10/602,447

ART UNIT :

: Unknown

FILED

: June 23, 2003

PAPER NO

FOR

: Method of Treating Deficit Hyperactivity Disorder

Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Dotodi

425/04

Respectfully submitted,

David R. Kurlandsky
Registration No. 41,505
Warner-Lambert Company
2800 Plymouth Road
App Arbor, MI 48105

Ann Arbor, MI 48105 Telephone: (734) 622-7304

Facsimile: (734) 622-1553

/	OIPE	25
	MAR 0 3 MOCK	THEE S
/	The Townself	Substi

J

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/602,447				
Filing Date	June 24, 2003				
First Named Inventor	Erik Ho Fong Wong				
Art Unit					
Examiner Name					
Attorney Docket Number	00054.US1 (PC24974A)				

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2831027	04-15-1958	Karl Pfister III, et al.	
		US-4788189	11-29-1988	Howard I. Glazer	
		US- 5316759	05-31-1994	Jed E. Rose, et al.	
		US- 5574052	11-12-1996	Jed E. Rose, et al.	
		us- 6004970	12-21-1999	Stephanie O'Malley, et al.	
		US- 6197827	03-06-2001	Douglas D. Cary	
		us- 6262049	07-17-2001	Vicki L. Coffin, et al.	
		US- 6352986	03-05-2002	Fred Hassan, et al.	
		US-			
		US-			
		US-			
•		US-			
		US-			

		FORE	IGN PATENT DOCU	JMENTS				
Examiner Initials*	Cite No.1			Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	, ,	Or Relevant Figures Appear	T ⁶		
	*	WO 94/28888	12-22-1994	Manuel F. Balandrin, et al				
	+	WO 99/52531	10-21-1999	Fred Hassan, et al.				
	#	WO 99/58130	11-18-1999	Duncan P. Taylor, et al.				
	+	DE 10004547	08-09-2001	Rainer K. Liedtke				
						_		
						П		

Examiner	Date	
Signature	. Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info<u>rmation unless</u> it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
000011101	0 10. 10 17.0 10			Application Number	10/602,447	
INFO	DRMATION	I DIS	CLOSURE	Filing Date	June 24, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Erik Ho Fong Wong	
	// to a second second second	4		Art Unit		
	(Use as many sh	eets as ne	ecessary)	Examiner Name		
Sheet	2	of	3	Attorney Docket Number	00054.US1 (PC24974A)	\mathcal{I}

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	F. BENAZZI, et al., "Urinary Retention With Reboxetine-Fluoxetine Combination in a Young Man", Canadian Journal of Psychiatry, December 2000, pp 936, Vol. 45, No. 10	
	+	A. R. CAGGIULA, et al., " Different Methods of Assessing Nicotine-Induced Antinociception May engage Different Neural Mechanisms", Psychopharmacology, 1995, pp 301-306, Vol. 122	
	4	M. W. DECKER, et al., "Erysodine, a Competitive Antagonist at Neuronal Nicotinic Aetylcholine Receptors", European Journal of Pharmacology, 1995, pp 79-89, Vol 280	
	+	J. N. DIANA, et al., "Nicotine-induced Skeletal Muscle Vasodilation is Mediated by Release of Epinephrine from Nerve Terminals", American Journal of Physiology, 1990, pp H1718-H1729, Vol. 259	
	+	B. E. GARRETT, et al., "Tobacco Addiction and Pharmacological Interventions", Expert Opinion of Pharmacotherapy, 2001, pp 1545-155, Vol. 2, No. 10	
	,	T. HISAYAMA, et al., "Mechanism of Action of Nicotine in Isolated Urinary Bladder of Guinea-pig", British Journal of Pharmacology, 1988, pp 465-472, Vol. 95	
	X	J. R. HUGHES, et al., "Anxiolytics for Smoking Cessation", 2002, Issue 1, Cochran Database of Systematice Reveiws	
	X	C. L. NUNN-THOMPSON, et al., " Pharmacotherapy for Smoking Cessation", Clinical Pharmacy, October 1998, pp 710-720, Vol. 8	
	*	K. S. OKUYEMI, et al., "Pharmacotherapy of Smking Cessation", Arch Farm Med, March 2000, pp 270-281, Vol. 9	
	4	C. RAPIER, et al., "Nicotinic Modulation of [3H] Dopamine Release from Striatal Synaptosomes: Pharmacological Characterisation", Journal of Neurochemistry, 1990, pp 937-945, Vol. 54, No. 3	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PT0				Complete if Known		
Substitute to form 1443/F10				Application Number	10/602,447	
INFO	DRMATION	I DIS	CLOSURE	Filing Date	June 24, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Erik Ho Fong Wong	
	***			Art Unit		
	(Use as many she	ets as ne	ecessary)	Examiner Name		
Sheet	3	of	3	Attorney Docket Number	00054.US1 (PC24974A)	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	+	I. P. STOLERMAN, et al., "Selective Antagonism of Behavioural Effects of Nicotine by Dihydro-Beta-Erythroidine in Rats", Psychopharmacology, 1997, pp 390-397, Vol. 129	
	Ŧ	F. S. TENNANT, et al., "Withdrawal From Nicotine Dependence Using Mecamylamine: Comparison of Three-Week and Six-Week Dosage Schedules", NIDA Research Monograph, 1984, pp 291-297, Vol. 55	:
	1	V. E. WOTRING, et al., "The Inhibitory Effects of Nicotinic Antagonists on Currents Elicited by Gaba in Rat Hippocampal Neurons", Neuroscience, 1995, pp 293-300, Vol. 67, No. 2	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.